Table 5.

Repeated testing of LA positive patients using anticoagulant drugs in cohorts aPL^neg, aPL^low.

	Patients with anticoagulants at		LA positivea with anticoagulants
	1st testing	2nd testing	Continued	Discontinued
Rivaroxaban, n	83a	50	26/50 (52%)	2/33 (6%)
VKA, n	60a	44	18/44 (41%)	1/16 (6%)
Other, n	15a	10	8/10 (80%)	0/5 (0%)
Total, n	158	104	52/104 (50%)	3/54 (6%)b

dRVVT, dilute Russell viper venom time; VKA, vitamin K antagonist.

^aPatients with a prolonged dRVVT screen and a dRVVT ratio > 1.2, and/or a prolonged aPTT and a ratio of LA-sensitive aPTT/aPTT > 1.2.

^bIn the cohort aPL^neg 0/40 patients with discontinued anticoagulant treatment were tested repeatedly positive for LA activity.